Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 4INDUSTRY 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Primary Myelofibrosis 3Neoplasms 3

Interventions

pembrolizumab 604Carboplatin 374Paclitaxel 283Cisplatin 270Gemcitabine 252Pemetrexed 194Bevacizumab 191Docetaxel 186Nivolumab 180Injections 169Cyclophosphamide 150atezolizumab 139Fluorouracil 134Capecitabine 133Oxaliplatin 132Dexamethasone 128durvalumab 113Fulvestrant 113130-nm albumin-bound paclitaxel 110fludarabine 103Cetuximab 100Leucovorin 97Rituximab 95venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 77Azacitidine 74Irinotecan 73Doxorubicin 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × navitoclax × 1 year × Clear all
NCT04472598 2026-03-23

TRANSFORM-1

AbbVie

Phase 3 Completed
252 enrolled 17 charts
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

AbbVie

Phase 3 Active not recruiting
330 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Active not recruiting
21 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡